The global superficial punctate keratitis treatment market is slated to reach a valuation of USD 5.3 billion in 2023. According to Future Market Insights, the market is expected to grow at a 6.33% CAGR until 2033, valued at USD 9.6 billion.
The rising incidence of the contagious disease is driving the superficial punctate keratitis treatment market, where the disease becomes more prevalent as soon as the temperature rises. It is also discovered that such a type of disease is common in tropical regions, so a rise in the global temperature influences the incidence of keratitis, thereby propelling the market.
The global demand for keratitis treatment is being influenced by increasing medical spending. There have been a few advancements limiting sales growth. With major investments, the keratitis treatment market provides the opportunity for detecting coronary eye disease by retaining a good perception throughout the coming years. But this disease is spreading due to poor sanitary conditions in developing nations.
The disease is spreading as a result of poor sanitary conditions in developing nations. Wearing contact lenses while swimming is another aspect ramping up the contamination of the eye, which is contributing to the contribution of the keratitis treatment.
North America is said to have the dominant share due to the rapid usage of modernization and contact lens, but individuals living in developing countries, especially in remote regions are said to get more affected due to the lacking access to healthcare providers because of low revenues.
| Attributes | Details |
|---|---|
| Projected Forecast Value (2023) | USD 5.3 billion |
| Projected Forecast Value (2033) | USD 9.6 billion |
| Growth rate | 6.33% CAGR |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global superficial punctate keratitis treatment market grew at a CAGR of 5.56% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
The patient may give a history of previous episodes, corneal abrasion due to contact lens wear, or oral or nasal sores. They might be taking topical or systemic steroids. The patient might have a history of immune deficiency state, or even recent fever or sun/UV exposure.
Recently, surgical intervention may be an option for patients with refractory SPK not responding to medical treatment and severe fungal infections. Penetrating keratoplasty is considered the most common surgical intervention for serious fungal keratitis and cases with perforation or impending perforation.
Recent advances have added more options such as targeted drug delivery at the site of infection in the form of intrastromal injections, collagen cross-linking, and rose Bengal-aided photodynamic therapy.
Launch of new drugs
The increase in research for and development activities conducted by numerous key players to launch new drugs are set to propel the market shortly. The rising cases of superficial keratitis are another major factor that is estimated to bode well for the Superficial Punctuate Keratitis Treatment Market.
According to World Health Organization (WHO), nearly 3.7 billion people under the age of 50 have superficial keratitis. Thus, these numbers are propelling the growth in this market.
Prevalence of infectious diseases
The superficial punctuate keratitis treatment market is also primarily driven due to the increase in the prevalence of infectious diseases. The disease increases with the increase in the temperature frequency. It is also found to be common in tropical regions thus increase in the global temperature drives the incidence of superficial punctuate keratitis thereby driving the market.
Principal Consultant
The cost of superficial punctuate keratitis treatment is very high. According to a study conducted by a team of researchers at Saint Louis University, people in the United States of America are said to spend 10 million for the treatment of this condition.
People, especially in emerging economies may not be able to spend huge amounts and this may hamper the superficial punctuate keratitis treatment in the future.
Polymerase Chain Reaction (PCR) is highly sensitive, but a large variation has been observed in numerous studies between the rates of SPK detection by PCR when compared to clinical diagnosis. PCR diagnostic effectiveness may be affected in patients under prophylactic anti-viral treatment with acyclovir.
In addition, topical anesthetics and dyes, such as fluorescein, Bengal rose and lissamine green used for clinical diagnosis of SPK may result in decreased sensitivity of the PCR assay. The type of specimen used in the detection of SPK with PCR is also an important factor.
Tear specimen produces significantly fewer sensitive results than corneal scrapings. PCR and in situ, hybridization are effective and powerful techniques when other virological procedures are non-contributive, particularly in immunocompromised patients previously treated with antiviral drugs.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The treatment of superficial punctuate keratitis usually involves medicine, including eye drops or antiviral medications taken by mouth. Surgery is rarely necessary but may be considered if scarring on the eye from superficial punctuate keratitis causes vision problems.
Each case of superficial punctuate keratitis is unique, and an eye doctor should determine the apt treatment for each patient. While some treatments can greatly lower the severity and recurrence of symptoms, there is no cure for the superficial punctuate keratitis market.
North America is projected to remain at the forefront by procuring the dominance of Superficial Punctuate Keratitis Market share shortly. The increase in the prevalence of infections associated with superficial punctuate keratitis in the USA is a leading factor that is likely to propel the market.
According to the Centers for Disease Control and Prevention (CDC), 1 in 5 individuals have a Sexually Transmitted Infection (STI), such as genital herpes in the USA totaling around 68 million infections. Therefore, this trend is projected to continue throughout the evaluation period, thereby boosting the Northern market.
The growing number of new product launches by reputed companies is expected to fuel the sales of superficial punctuate keratitis treatment options in the Asia Pacific. The surging number of clinical trials in China, Singapore, and Malaysia is another significant factor that is estimated to augur well for the market.
The demand for hospital pharmacies will be more during the forecast period.
According to a report by Future Market Insights, the hospital pharmacies would grow within the anticipated time frame. This market sector is expected to hold a greater share of the worldwide superficial punctuate keratitis treatment market from 2023 to 2033.
Due to the growing number of people visiting hospitals for advice on treatment related to hormonal cancer, the hospital pharmacy is anticipated to dominate the worldwide superficial punctuate keratitis treatment market. As a result, individuals more pertain towards their health and well-being. Thus, the majority of consumers are expected to only buy medications from hospital pharmacies.
Amphotericin B is said to dominate the market share
Amphotericin B deoxycholate (AMB-d) is FDA-indicated for treating life-threatening or potentially life-threatening fungal infections: aspergillosis, cryptococcosis, blastomycosis, systemic candidiasis, coccidioidomycosis, histoplasmosis, and mucormycosis.
AMB-d is also approved for treating the parasitic disease American mucocutaneous leishmaniasis. AMB-d has an off-label use for esophageal candidiasis (both HIV-infected and non-HIV infected adults and adolescents; HIV-exposed and or infected infants and children), fluconazole-refractory oropharyngeal candidiasis, candidal endophthalmitis, candidal urinary tract infections, visceral leishmaniasis, and ophthalmic aspergillosis.
Some of the prominent players in the global market are-
Some of the important developments of the key players in the market are:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 6.33% from 2023 to 2033 |
| Market value in 2023 | USD 5.3 billion |
| Market value in 2033 | USD 9.6 billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD billion for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Class, Route of Administration, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC countries, South Africa, Israel |
| Key Companies Profiled | Dompé Farmaceutici; Allergan; Bausch Health Companies Inc.; CONTACARE; OHTO Pharmaceutical Co., Ltd.; Pfizer, Inc.; Neuroptika; Santen Pharmaceutical Co., Ltd.; Johnson & Johnson; Grand Pharma Co., Ltd.; Zhejiang CONBA Pharmaceutical Co., Ltd. |
| Customisation Scope | Available on Request |
In 2023, the market is expected to be worth USD 5.3 billion.
By 2033, the United Kingdom is anticipated to dominate a 9.2% market share.
The market is expected to continue growth at an 6.33% CAGR until 2033.
From 2018 to 2022, the global market advanced at a CAGR of 5.56%.
Amphotericin B is considered to have a dominant position on the market.
The market is expected to be around USD 9.6 billion by 2033.
1. Executive Summary | Superficial Punctate Keratitis Treatment Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Amphotericin B 5.2. Griseofulvin 5.3. Voriconazole 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Oral 6.2. Topical 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Hospital Pharmacies 7.2. Retail Pharmacies 7.3. Online Pharmacies 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. MEA 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Dompe farmaceutici S.p.A. 18.2. Allergan 18.3. Bausch Health Companies Inc. 18.4. CONTACARE 18.5. OHTO Pharmaceutical Co., Ltd. 18.6. Pfizer, Inc. 18.7. Neuroptika 18.8. Santen Pharmaceutical Co., Ltd. 18.9. Johnson & Johnson 18.10. Grand Pharma Co., Ltd. 18.11. Zhejiang CONBA Pharmaceutical Co., Ltd. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Superficial Punctate Keratitis Treatment Market
